On Friday, Intra-Cellular Therapies Inc (NASDAQ: ITCI) opened higher 14.91% from the last session, before settling in for the closing price of $82.56. Price fluctuations for ITCI have ranged from $62.78 to $93.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 9522.17% over the past five years. Company’s average yearly earnings per share was noted 57.29% at the time writing. With a float of $99.09 million, this company’s outstanding shares have now reached $106.00 million.
Let’s look at the performance matrix of the company that is accounted for 610 employees. In terms of profitability, gross margin is 92.29%, operating margin of -19.84%, and the pretax margin is -13.89%.
Intra-Cellular Therapies Inc (ITCI) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Intra-Cellular Therapies Inc is 6.53%, while institutional ownership is 90.68%. The most recent insider transaction that took place on Dec 04 ’24, was worth 4,375,659. In this transaction Chairman and CEO of this company sold 51,000 shares at a rate of $85.80, taking the stock ownership to the 1,070,329 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chairman and CEO sold 51,697 for $84.08, making the entire transaction worth $4,346,842. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.29% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Check out the current performance indicators for Intra-Cellular Therapies Inc (ITCI). In the past quarter, the stock posted a quick ratio of 7.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.48 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Intra-Cellular Therapies Inc (NASDAQ: ITCI) saw its 5-day average volume 1.27 million, a positive change from its year-to-date volume of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 47.54%. Additionally, its Average True Range was 3.23.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 87.18%, which indicates a significant increase from 79.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.13% in the past 14 days, which was higher than the 36.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $85.48, while its 200-day Moving Average is $75.78. Nevertheless, the first resistance level for the watch stands at $100.09 in the near term. At $105.32, the stock is likely to face the second major resistance level. The third major resistance level sits at $112.24. If the price goes on to break the first support level at $87.95, it is likely to go to the next support level at $81.03. Assuming the price breaks the second support level, the third support level stands at $75.80.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
There are currently 106,017K shares outstanding in the company with a market cap of 10.06 billion. Presently, the company’s annual sales total 464,370 K according to its annual income of -139,670 K. Last quarter, the company’s sales amounted to 175,380 K and its income totaled -26,320 K.